Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era
Authors:
- 1 October 2011
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 25 (5) , 1025-1048
Abstract
No abstract availableKeywords
This publication has 136 references indexed in Scilit:
- Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasBlood, 2011
- HLA-Identical Sibling Compared With 8/8 Matched and Mismatched Unrelated Donor Bone Marrow Transplant for Chronic Phase Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2009
- The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upHaematologica, 2009
- Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemiaLeukemia & Lymphoma, 2009
- Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2008
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemiaBlood, 2008
- Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved SurvivalTransplantation and Cellular Therapy, 2007
- Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow TransplantationBlood, 2006
- Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome–positive leukemiaBlood, 2006
- The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemiaBlood, 2006